Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 5/20 | 0.38 |
| ▸ | MAOB | P27338 | 5/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098422 | 0.91 | MCHR1 (0.41) | MCHR1MAOAMAOBGRM1NTRK1 | |
| SCHEMBL4093619 | 0.86 | MCHR1 (0.41) | MCHR1MAOAMAOBGRM1NPC1 | |
| SCHEMBL5436198 | 0.83 | ALDH1A2 (0.40) | MAOAMAOB | |
| SCHEMBL4791971 | 0.81 | TACR2 (0.41) | GRM1SMN1; SMN2POLB | |
| SCHEMBL4093553 | 0.80 | MAOA (0.43) | MAOAMAOBNPC1CNR1SMN1; SMN2 | |
| SCHEMBL4104142 | 0.79 | MAOA (0.42) | MAOAMAOBNPC1CNR1SMN1; SMN2 | |
| SCHEMBL4107328 | 0.77 | MAOB (0.40) | MAOAMAOBCNR1SMN1; SMN2HIF1A | |
| SCHEMBL4097406 | 0.77 | MCHR1 (0.41) | MCHR1MAOAMAOBGRM1NPC1 | |
| SCHEMBL27670851 | 0.77 | POLB (0.33) | MCHR1GRM1CNR1POLB | |
| SCHEMBL5427490 | 0.75 | CNR1 (0.33) | MCHR1NPC1RAB9ACNR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2009-09-17 | — | — | US | claimed |
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | TRPV1, TRPV2, TRPV3 | MCHR1 473/4885MAOA 3635/4885MAOB 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.